RALLYBIO CORPORATION Increase (Decrease) in Prepaid Expense and Other Assets
RALLYBIO CORPORATION (RLYB) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$2.29 million for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-26
- RALLYBIO CORPORATION increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$2.44M, a 254.72% decline year-over-year.
- RALLYBIO CORPORATION increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $155.00K, a 69.37% decline year-over-year.
- RALLYBIO CORPORATION increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$815.00K.
- RALLYBIO CORPORATION increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $773.00K, a 251.36% increase year-over-year.
- RALLYBIO CORPORATION increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$5.82M, a 225.27% decline from fiscal 2022.
- RALLYBIO CORPORATION increase (decrease) in prepaid expense and other assets for fiscal 2022 was $4.64M, a 3.06% increase from fiscal 2021.
- RALLYBIO CORPORATION increase (decrease) in prepaid expense and other assets for fiscal 2021 was $4.51M.
- RALLYBIO CORPORATION increase (decrease) in prepaid expense and other assets for fiscal 2020 was -$434.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.44M derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | -$2.29M S-4/A · filed 2026-08-26 | -$3.10M derived: sum of 3 quarters · filed 2026-08-26 | -$2.33M derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | $155.00K S-4 · filed 2026-07-15 | -$660.00K derived: sum of 2 quarters · filed 2026-08-26 | $113.00K derived: sum of 3 quarters · filed 2026-08-26 | $1.69M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | -$815.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | -$42.00K derived: sum of 2 quarters · filed 2026-08-26 | $1.54M derived: sum of 3 quarters · filed 2026-08-26 | $2.04M S-4/A · filed 2026-08-26 |
| 2025-09-30 | $773.00K derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-06 | $2.35M derived: sum of 2 quarters · filed 2026-08-26 | $2.86M 10-Q · filed 2025-11-06 | $2.05M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | $1.58M derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | $2.08M S-4/A · filed 2026-08-26 | $1.27M derived: sum of 3 quarters · filed 2026-08-26 | $1.50M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | $506.00K S-4 · filed 2026-07-15 | -$304.00K derived: sum of 2 quarters · filed 2026-08-26 | -$84.00K derived: sum of 3 quarters · filed 2026-08-26 | -$1.68M derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | -$810.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | -$590.00K derived: sum of 2 quarters · filed 2026-08-26 | -$2.19M derived: sum of 3 quarters · filed 2026-08-26 | -$2.72M S-4/A · filed 2026-08-26 |
| 2024-09-30 | $220.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.38M derived: sum of 2 quarters · filed 2025-11-06 | -$1.91M 10-Q · filed 2025-11-06 | -$8.13M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$2.13M 10-Q · filed 2025-08-07 | -$8.35M derived: sum of 3 quarters · filed 2025-08-07 | -$6.36M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$537.00K 10-Q · filed 2025-05-08 | -$6.76M derived: sum of 2 quarters · filed 2025-05-08 | -$4.76M derived: sum of 3 quarters · filed 2025-05-08 | -$6.70M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$6.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$4.22M derived: sum of 2 quarters · filed 2025-03-13 | -$6.16M derived: sum of 3 quarters · filed 2025-03-13 | -$5.82M 10-K · filed 2025-03-13 |
| 2023-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $60.00K derived: sum of 2 quarters · filed 2024-11-07 | $400.00K 10-Q · filed 2024-11-07 | $1.10M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.59M 10-Q · filed 2024-08-08 | -$898.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.74M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $340.00K 10-Q · filed 2024-05-09 | $1.04M derived: sum of 2 quarters · filed 2024-05-09 | $3.68M derived: sum of 3 quarters · filed 2024-05-09 | $4.19M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $697.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $3.34M derived: sum of 2 quarters · filed 2024-03-12 | $3.85M derived: sum of 3 quarters · filed 2024-03-12 | $4.64M 10-K · filed 2024-03-12 |
| 2022-09-30 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.15M derived: sum of 2 quarters · filed 2023-11-09 | $3.95M 10-Q · filed 2023-11-09 | $4.07M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $514.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.31M 10-Q · filed 2023-08-08 | $1.43M derived: sum of 3 quarters · filed 2023-08-08 | $3.57M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $794.00K 10-Q · filed 2023-05-09 | $915.00K derived: sum of 2 quarters · filed 2023-05-09 | $3.05M derived: sum of 3 quarters · filed 2023-05-09 | $5.36M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $2.26M derived: sum of 2 quarters · filed 2023-03-06 | $4.57M derived: sum of 3 quarters · filed 2023-03-06 | $4.51M 10-K · filed 2023-03-06 |
| 2021-09-30 | $2.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $4.45M derived: sum of 2 quarters · filed 2022-11-07 | $4.39M 10-Q · filed 2022-11-07 | $3.88M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $2.25M 10-Q · filed 2022-08-08 | $1.74M derived: sum of 3 quarters · filed 2022-08-08 | $1.14M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$61.00K 10-Q · filed 2022-05-10 | -$570.00K derived: sum of 2 quarters · filed 2022-05-10 | -$1.17M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$509.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$1.11M derived: sum of 2 quarters · filed 2022-03-15 | -$434.00K 10-K · filed 2022-03-15 | |
| 2020-09-30 | -$604.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $75.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $679.00K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |